Alberto Dalla Volta

8PUBLICATIONS
19CO-AUTHORS
Molecular targetsMedical biochemistry - proteins and peptides (incl. medical proteomics)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 03, 2025
Addition of zoledronic acid to enzalutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: the randomized phase II BONENZA trial.

Alberto Dalla Volta, Francesca Valcamonico, Andrea Zivi

|Jul 26, 2024
Fat Fraction Extracted from Whole-Body Magnetic Resonance (WB-MR) in Bone Metastatic Prostate Cancer: Intra- and Inter-Reader Agreement of Single-Slice and Volumetric Measurements.

Giorgio Maria Agazzi, Nunzia Di Meo, Paolo Rondi

|Apr 24, 2024
Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.

Marco Bergamini, Alberto Dalla Volta, Carlotta Palumbo

|Aug 16, 2022
Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.

Carlotta Palumbo, Alberto Dalla Volta, Stefania Zamboni

|Nov 23, 2021
Is BMI a reliable prognostic parameter in metastatic prostate cancer patients?

Irene Caramella, Alberto Dalla Volta, Francesca Valcamonico

|Mar 16, 2021
Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study.

Carlotta Palumbo, Alessandro Antonelli, Luca Triggiani

Pageof 2

Frequent Collaborators

3 joint publications

Carlotta Palumbo

3 joint publications

Alfredo Berruti

3 joint publications

Roberto Maroldi

2 joint publications

Sandra Sigala